Zolmitriptan Od Tablet, Orally Disintegrating
Product Images NDC 42291-998

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zolmitriptan Od (NDC 42291-998). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (998 06)

1 (998 06)
Packaging label for Zolmitriptan Orally Disintegrating Tablets, USP 2.5 mg, a human prescription drug by AvKARE. The label indicates a package of 6 unit-dose tablets with storage instructions, manufacturer details, and dosage strength prominently displayed. It is for oral use and includes a barcode and regulatory information.*
FDA Label Image

1 (999 03)

1 (999 03)
Packaging label for Zolmitriptan OD 5 mg orally disintegrating tablets by AvKARE. The label indicates the product contains 5 mg of zolmitriptan per tablet, supplied in unit-dose form with a total of 3 tablets. Storage instructions and prescribing information guidance are also present, along with manufacturer and barcode details.*
FDA Label Image

Zolmitriptan Structure (Structure)

Zolmitriptan Structure (Structure)
Chemical structure diagram of the active ingredient zolmitriptan, showing its molecular bonds and groups in a two-dimensional format.*
FDA Label Image

Fig 1 (Figure 1)

Fig 1 (Figure 1)
Line graph showing the estimated probability of response over time from initial dose for placebo and zolmitriptan at 1 mg, 2.5 mg, and 5 mg doses. The y-axis represents the probability percentage, and the x-axis shows time points at 0, 1, 2, 3, and 4 hours. Each dose group follows a distinct curve indicating response trends over the 4-hour period.*
FDA Label Image

Fig 2 (Figure 2)

Fig 2 (Figure 2)
A line graph showing the estimated probability of medication rescue over 24 hours from the initial dose, comparing placebo and three zolmitriptan doses (1 mg, 2.5 mg, 5 mg). The probability increases over time, with placebo showing the highest curve, followed by 1 mg, 2.5 mg, and 5 mg doses. The x-axis represents time in hours, and the y-axis shows probability percentage up to 100%.*
FDA Label Image

Fig 3 (Figure 3)

Fig 3 (Figure 3)
A line graph comparing the estimated probability of response over time between Zolmitriptan Orally Disintegrating Tablets 2.5 mg and placebo. The x-axis represents time from the initial dose (0 to 2 hours), and the y-axis shows estimated probability of response (0% to 100%). Two lines show increasing response over 2 hours, with Zolmitriptan OD tablets having a higher probability than placebo at all time points.*
FDA Label Image

Fig 4 (Figure 4)

Fig 4 (Figure 4)
A line graph comparing the estimated probability of remediation or rescue over 24 hours between Placebo and Zolmitriptan Orally Disintegrating Tablets 2.5 mg. The x-axis shows time in hours from the initial dose, and the y-axis shows the estimated probability percentage, with Placebo represented by a dotted line and Zolmitriptan 2.5 mg by a solid line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.